Q&A: The Cancer Tradeoff

Physicist-turned-oncologist Robert Austin argues that cancer is a natural consequence of our rapid evolution.

Written byChris Palmer
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Princeton physicist Robert AustinCOURTESY OF ROBERT AUSTINCancer mortality rates have, on average, not budged for the past 40 years, despite billions of dollars in annual research expenditures. Looking for fresh insights into cancer research, the National Institutes for Health in 2009 launched 12 physical science oncology centers at universities around the United States. The funders hope cancer research, which has benefited from tools made by physicists, can also benefit from physicists’ unique perspective on cancer as a physical system.

Among the directors of these centers, Princeton University’s Robert Austin holds perhaps the most controversial perspectives on cancer. Austin, a trained physicist and a member of the National Academy of Sciences, believes we might have cancer for a reason. It’s a tradeoff, he says, for the rapid evolution our species has leveraged to become the dominant force on the planet. He also suggests that cancer might act as a form of global population control, possibly serving to increase species fitness.

One of the main challenges facing cancer researchers, Austin said, is a tumor’s ability to evolve resistance to chemotherapy. He thinks this trait shares many characteristics with antibiotic resistance among bacteria. To that end, his lab builds specially designed microenvironments to study how antibiotic resistance ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo